Dual inhibition, newer paradigms for cholesterol lowering

American Journal of Therapeutics
Srikanth KatragaddaRohit Arora

Abstract

Coronary heart disease (CHD) is the leading cause of death in United States. The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III recommends new lower cholesterol levels, particularly for patients at moderate and high risk for coronary disease. Low-density lipoprotein (LDL) cholesterol is primarily the target of hypolipidemic drugs. The NCEP ATP III recommends an LDL cholesterol goal of <100 mg/dL in high-risk patients and an LDL cholesterol goal of <70 mg/dL as a therapeutic option, especially in patients with very high risk of CHD. Statins are potent LDL cholesterol-lowering drugs, but they are not as effective as fibrates and niacin in improving levels of triglycerides or high-density lipoprotein cholesterol. Ezetimibe represents a new class of hypolipidemic drugs that inhibit cholesterol absorption in the small intestine. The combination of ezetimibe with statins has been more effective than monotherapy alone in many randomized trials. LDL cholesterol reduction with statin occurs mainly with the initial dose, with relatively smaller reductions seen at higher doses. Ezetimibe was also shown to be useful in various population subgroups such as African-Americans, men and women, elderly and aged, an...Continue Reading

References

May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·P H GrootL Havekes
Jan 15, 2000·Journal of the American College of Cardiology·C J VaughanC T Basson
Feb 19, 2000·Current Opinion in Lipidology·G F Watts, S B Dimmitt
Nov 22, 2000·The Journal of Clinical Investigation·A R Tall, N Wang
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Feb 12, 2002·The Journal of Clinical Endocrinology and Metabolism·Robert A Kreisberg, Albert Oberman
Sep 21, 2002·Lancet·Duncan M Geddes
Mar 14, 2003·The American Journal of Cardiology·Harold E BaysUNKNOWN ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation
Aug 26, 2003·Mayo Clinic Proceedings·Michael Miller
Feb 21, 2004·Science·Scott W AltmannMichael P Graziano
May 26, 2004·The American Journal of Clinical Nutrition·Roger S McLeodDeborah L Currie
Jan 26, 2005·Mayo Clinic Proceedings·William L Lanier
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jun 9, 2005·Journal of Atherosclerosis and Thrombosis·Akio Kawakami, Masayuki Yoshida
Jun 25, 2005·Circulation Research·Gary F Lewis, Daniel J Rader
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Jan 13, 2006·Circulation·Thomas ThomUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 26, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M KohnleO Witzke
Jul 29, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Heiner K BertholdIoanna Gouni-Berthold
Oct 7, 2006·Current Medical Research and Opinion·Alberico L CatapanoAndrew M Tershakovec
Dec 6, 2007·Preventive Cardiology·Lori Mosca

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.